Drug Profile
Research programme: neuropathic pain therapeutics - NanoAxis
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator NanoAxis
- Class Analgesics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Neuropathic pain in USA (Parenteral) (NanoAxis website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Parenteral)
- 18 Jul 2016 Research programme: neuropathic pain therapeutics - NanoAxis is available for licensing- http://www.nanoaxisllc.com/Neuroscience.html